Researchers have identified how the bacteriophage protein AcrIIA27 inhibits diverse Cas9 enzymes by binding solvent-exposed regions of the guide RNA rather than the protein itself. This structural ...

A mutation-agnostic CRISPR-Cas strategy that inserts a functional rhodopsin coding sequence into the human RHO locus has ...

Base editing offers far more versatility than its name implies. The technique was initially developed to correct ...

A recent British study at the University of Bristol indicates that the last universal common ancestor (LUCA) possessed an early form of the CRISPR-Cas immune system, dating back approximately 4.2 ...

On 28 January 2026, nChroma Bio dosed the first participant in its Phase 1/2 clinical trial of CRMA-1001, an investigational CRISPR-Cas-based epigenetic silencer targeting chronic hepatitis B virus ...

Delivering a CRISPR-Cas-derived adenine base editor as a short-lived protein-guide RNA complex enabled efficient PCSK9 ...

The company’s lead candidate, AXL-003, is advancing towards preclinical evaluation in an autoimmune indication with liver-targeted delivery. This programme builds directly on results showing that AXL ...

RAVYN, a biotech intelligence tool that curbs $100M/year in wasted executive time, will debut at a live event today, Friday, January 9, at 6:00 PM CET. Designed to end unproductive news-scanning, it ...

A mutation-agnostic CRISPR-Cas strategy that inserts a functional rhodopsin coding sequence into the... Base editing expands its scope through advances in... CRISPR Trials Global Overview Q2 2026 from ...

The team behind Ariya Bio, from left to right: Mierelle Schuijt (Research Associate), Aniruddhan Balakrishnan (Corporate Strategy Intern), Mandy Boontanrart (Cofounder), Maike Getwan (Research Intern) ...

Conventional CRISPR-CAS9 tools trigger immune responses in host animals, which can systematically distort screening results and mask genuine cancer vulnerabilities. A novel platform called StealTHY ...